Clinical Trials Logo

HIV-1 Infection clinical trials

View clinical trials related to HIV-1 Infection.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05584397 Enrolling by invitation - HIV Clinical Trials

Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART

Start date: September 1, 2022
Phase:
Study type: Observational

The goal of the project is to determine the difference in immune activation and HIV reservoir size between People living with HIV (PWH) on tenofovir-containing antiretroviral therapy (ART) versus PWH on nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART. Tenofovir (TFV), a phosphonated nucleoside reverse transcriptase inhibitor (NRTI), is being used for oral pre-exposure prophylaxis (PrEP). The investigators will test this hypothesis: tenofovir, and perhaps NRTIs in general, stimulate a type I/III interferon also in PWH who take these drugs. Because chronic interferon stimulation may promote the survival and proliferation of cells with integrated provirus, the investigators also hypothesize that these drugs antagonize decay of the HIV latent reservoir in PWH on ART. Consequently, the researchers hypothesize that PWH who have switched from NRTI-containing ART to NRTI-sparing ART exhibit lower type I/III interferon pathway activation and lower latent HIV reservoir size. The investigators also hypothesize that independently of treatment, the extent of type I/III interferon activation correlates with latent HIV reservoir size. Thus, the proposed study seeks to answer these two questions. Can the gastrointestinal epithelium be impacted by ART, and contribute to chronic immune activation and expansion of the HIV-1 reservoir? If so, what therapeutic approaches can the investigators implement to reduce the HIV-1 proviral load? The data will reveal pathways that can be targeted therapeutically to treat chronic immune activation in PWH. The findings of this study will immediately translate to optimize the standard of care in PWH.

NCT ID: NCT05314088 Enrolling by invitation - Clinical trials for Stress, Psychological

Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV

RISE+
Start date: February 3, 2023
Phase: N/A
Study type: Interventional

This study will examine the mechanisms and efficacy of a resilience building intervention in older people living with HIV.

NCT ID: NCT05143307 Enrolling by invitation - HIV-1-infection Clinical Trials

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

Start date: July 11, 2023
Phase: Phase 1
Study type: Interventional

Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).

NCT ID: NCT05040308 Enrolling by invitation - HIV-1-infection Clinical Trials

Uganda PrEP and Harm Reduction Evaluation

Start date: February 11, 2022
Phase: N/A
Study type: Interventional

This is an evaluation of programs to integrate PrEP into existing services for PWUD. PrEP will be delivered according to Uganda national guidelines and data from national monitoring and evaluation forms will be leveraged to address key outcomes. Additionally, research components will be implemented to support greater understanding of PrEP use and experiences of participants engaged with the PrEP programs.

NCT ID: NCT04605354 Enrolling by invitation - Hiv Clinical Trials

Epidemiological and Clinical Description of Women Living With HIV in Selected Countries of Latin America

Start date: July 1, 2020
Phase:
Study type: Observational

A cross-sectional study that uses ecological data from (1) PLWHIV under care at 31st December 2017, and (2) from yearly admissions to care occurred during 2013 - 2017, from centers belonging to LAW-HIV.

NCT ID: NCT03567304 Enrolling by invitation - HIV-1-infection Clinical Trials

Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine

Start date: July 6, 2018
Phase: Phase 4
Study type: Interventional

People living with HIV in the era of antiretroviral therapy (ART) continue to suffer high rates of neurocognitive disorder. This is a randomized control trial aiming to evaluate improvement of neurocognitive function after switching efavirenz (EFV) to rilpivirine (RPV). EFV based regimen is currently the first line ART in Thailand. There are several reports suggested that HIV-infected patients who took EFV based regimen had poorer neurocognitive function compared to the comparator. RPV, another first line regimen, has been known to have less neuropsychiatric side effects. We hypothesized that switching EFV to RPV could improve neurocognitive function.